VEGF blockade: Optimizing chemotherapy drug uptake
New research is showing that sequence and timing have significant impact on the efficacy of therapeutic regimens that include bevacizumab.
New research is showing that sequence and timing have significant impact on the efficacy of therapeutic regimens that include bevacizumab.
A vaccine for people newly diagnosed with glioblastoma multiforme—the most aggressive and highest-grade malignant glioma—is being tested at 20 sites nationwide in a phase II trial.
Medications were able to block a newly identified cancer-promoting pathway and delay glioma growth in mice, suggesting a new treatment option to combat malignant glioma.
The FDA has approved a portable therapeutic system that can be used at home by adults who have glioblastoma that has recurred or progressed following chemotherapy and radiotherapy.
Using bevacizumab in combination with chemotherapy or biological therapy raises the risk of treatment-related death—but the agent’s potential benefits may outweigh the relatively low absolute risk.